Document Detail


Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation.
MedLine Citation:
PMID:  19910393     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Oral mucositis is a serious problem that affects a significant number of hematopoietic cell transplant (HCT) patients. There are many gaps in management, and evidence-based guidelines do not provide consistent recommendations. The purpose of this pilot study was to develop a mucositis oral care protocol for the prevention and management of mucositis in the HCT patient and to evaluate the clinical impact of its implementation.
METHODS: After receipt of Institutional Review Board approval, all patients admitted to the Hematology-Oncology service for high-dose chemotherapy followed by an autologous or allogeneic HCT were eligible for the study. As part of a change in practice, a new mucositis protocol consisting of a specific oral care regimen was instituted for prevention and treatment of mucositis. Assessment of mucositis began upon admission to the hospital and the patient was evaluated using a mucositis grading scale on a daily basis by the physician and nursing staff. The new mucositis protocol was a part of the HCT service admission orders for each patient. The group of patients treated according to the new mucositis protocol were compared with a retrospective control group consisting of patients who had undergone management of oral mucositis under the previous standard of care. The primary endpoints were to evaluate incidence, severity, and duration of oral mucositis. Secondary endpoints included days requiring narcotics; days of parenteral nutrition, febrile neutropenia, antimicrobial therapy, and length of hospital stay.
RESULTS: There were 13 patients enrolled in the control group and 12 patients in the new protocol group. The new protocol resulted in a decreased incidence (100% vs. 75%) and duration (19.2 vs. 8.3 days) of mucositis. Days of maximum grade one and three mucositis were decreased by 56%, and 70%, respectively. Days of maximum grade two mucositis, however increased by 22%. The days of narcotic use were reduced by 19% in the new protocol group (15.8 vs. 12.8 days). All patients in the new protocol group required parenteral nutrition, but days of use were reduced by 41% (17 vs. 10.2 days). The incidence of infection measured by days of febrile neutropenia and antimicrobial therapy were reduced by 35% (10.2 vs. 6.5 days) and 33% (17 vs. 11.4 days). Finally, the overall length of hospital stay was reduced by 7 days (30 vs. 23 days).
CONCLUSION: Implementation of a standardized oral care protocol for mucositis management resulted in a decreased incidence, duration and severity of mucositis, and also reduced the global negative impact of mucositis. Future studies may further evaluate the global impact by adjusting for confounding factors.
Authors:
Valkal Bhatt; Nancy Vendrell; Karen Nau; Deborah Crumb; Vivek Roy
Related Documents :
9013173 - Endoscopic nasogastric-jejunal feeding tube placement in critically ill patients.
24826783 - Effects of thymol on ca²⁺ homeostasis and apoptosis in mdck renal tubular cells.
16331173 - Subgroup analysis and covariate adjustment in randomized clinical trials of traumatic b...
Publication Detail:
Type:  Journal Article     Date:  2009-11-12
Journal Detail:
Title:  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners     Volume:  16     ISSN:  1477-092X     ISO Abbreviation:  J Oncol Pharm Pract     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-25     Completed Date:  2010-12-10     Revised Date:  2012-04-11    
Medline Journal Info:
Nlm Unique ID:  9511372     Medline TA:  J Oncol Pharm Pract     Country:  England    
Other Details:
Languages:  eng     Pagination:  195-204     Citation Subset:  IM    
Affiliation:
Department of Pharmacy, Mayo Clinic Florida, Jacksonville, FL, USA. Bhattv@mskcc.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Infective Agents, Local / therapeutic use
Antifungal Agents / therapeutic use
Clinical Protocols / standards*
Cryotherapy
Female
Fibroblast Growth Factor 7 / therapeutic use
Hematopoietic Stem Cell Transplantation / adverse effects*
Humans
Length of Stay
Male
Middle Aged
Mouthwashes / therapeutic use
Mucositis / etiology,  prevention & control*
Pilot Projects
Prospective Studies
Retrospective Studies
Standard of Care / organization & administration*
Chemical
Reg. No./Substance:
0/Anti-Infective Agents, Local; 0/Antifungal Agents; 0/Mouthwashes; 126469-10-1/Fibroblast Growth Factor 7
Comments/Corrections
Comment In:
J Oncol Pharm Pract. 2012 Mar;18(1):158   [PMID:  22392965 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Next Document:  Cultural conceptualizations of hospice palliative care: more similarities than differences.